Journal article
STAT inhibitors for cancer therapy
Journal of hematology and oncology, Vol.6(1), pp.90-90
12/05/2013
DOI: 10.1186/1756-8722-6-90
PMCID: PMC4029528
PMID: 24308725
Abstract
Signal Transducer and Activator of Transcription (STAT) proteins are a family of cytoplasmic transcription factors consisting of 7 members, STAT1 to STAT6, including STAT5a and STAT5b. STAT proteins are thought to be ideal targets for anti-cancer therapy since cancer cells are more dependent on the STAT activity than their normal counterparts. Inhibitors targeting STAT3 and STAT5 have been developed. These included peptidomimetics, small molecule inhibitors and oligonucleotides. This review summarized advances in preclinical and clinical development of these compounds.
Details
- Title: Subtitle
- STAT inhibitors for cancer therapy
- Creators
- Muhammad Furqan - Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY 10595, USAAkintunde Akinleye - Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY 10595, USANikhil Mukhi - Department of Medicine, SUNY Downstate Medical Center Brooklyn, Brooklyn, NY 11203, USAVarun Mittal - Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY 10595, USAYamei Chen - Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY 10595, USADelong Liu - Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY 10595, USA
- Resource Type
- Journal article
- Publication Details
- Journal of hematology and oncology, Vol.6(1), pp.90-90
- DOI
- 10.1186/1756-8722-6-90
- PMID
- 24308725
- PMCID
- PMC4029528
- NLM abbreviation
- J Hematol Oncol
- ISSN
- 1756-8722
- eISSN
- 1756-8722
- Publisher
- BioMed Central
- Language
- English
- Date published
- 12/05/2013
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984094333302771
Metrics
17 Record Views